NPO Microgen, a subsidiary of Nacimbio (part of Rostec Corporation), published its results for 2017. The company’s revenue reached 7.7 billion rubles.
Compared to 2016, the total output of medicines in packages increased by 16%, while the vaccines produced by Microgen became the most widely used drugs for free flu prevention in Russia.
In terms of revenue, positive dynamics was observed for the second year in a row. Net profit of the company was more than 498 million rubles.
In terms of output, the highest increase in 2017 was reported for immunomodulating agents (43%), blood-derived products (36%), and bacteriophages (29%).
In 2017, total supplies of Sovigripp vaccine for the needs of National Immunization Schedule exceeded 57 million doses. This vaccine was developed by NPO Microgen for flu prevention and is manufactured today by three Russian enterprises (Fort LLC, St. Petersburg Institute of Vaccines and Serums of FMBA of Russia, and NPO Microgen). As a result, the product of NPO Microgen captured more than 95% of the total market for flue vaccines used in the National Immunization Schedule.
“We view the past year as a success. In particular, we implemented key stages to commission new production facilities and integrate technologies aimed at improving the quality of our products. We developed new drugs, that can compete with their international analogs, and successfully completed various phases for a number of clinical trials,” said Kirill Gaidash, General Director of NPO Microgen.